Two neuropeptides, two origins
Semax and Selank are frequently discussed together in the research-peptide literature, often under the informal grouping of 'Russian nootropic peptides'. Both are short synthetic neuropeptides developed by Russian research institutions in the late twentieth century, and both are studied in preclinical and experimental models of the central nervous system. Their shared geographic and historical origin, together with a similar heptapeptide-class structure, is the main reason they are so often placed side by side.
Beyond that surface grouping, however, the two compounds are not variants of one another. They descend from entirely different parent molecules, are studied along distinct mechanistic pathways, and carry separate molecular identities. This article compares the two on the basis of what the published research describes, without ranking one above the other and without reference to any use beyond laboratory research.
What Semax is and where it comes from
Semax is a synthetic peptide derived from a fragment of adrenocorticotropic hormone (ACTH). Its sequence is based on the ACTH(4-10) region, an amino-acid stretch that had long been of interest in neuroscience research because ACTH fragments were observed to influence neural signalling without the full hormonal activity of the parent molecule. Semax is an analogue of this fragment, structurally modified so that it is more resistant to rapid breakdown by peptidases than the native sequence.
In the research literature, Semax is most often examined in the context of neurotrophic and neuromodulatory signalling. A recurring theme in published studies is its association with brain-derived neurotrophic factor (BDNF) and related pathways, which are of general interest in models of neuronal signalling and plasticity. These are described here strictly as mechanistic observations reported in experimental systems, not as effects claimed for any individual.
What Selank is and where it comes from
Selank is a synthetic analogue of tuftsin, a naturally occurring peptide fragment associated with immunomodulatory activity. As with Semax, the native parent sequence is short-lived in biological systems, and Selank was designed with structural modifications intended to improve stability relative to tuftsin. Its identity as a tuftsin analogue is central to how it is positioned in the literature, because it links Selank to research on neuroimmune signalling as well as to the nervous system more broadly.
In experimental models, Selank is studied predominantly in relation to GABAergic signalling and anxiolytic-associated pathways, alongside its tuftsin-derived neuroimmune activity. The research discussion around Selank therefore tends to sit at the intersection of neurological and immunological signalling, which distinguishes its studied mechanisms from those attributed to Semax.
Comparing the mechanisms studied
The clearest way to separate the two compounds is by parent molecule and studied pathway. Semax originates from an ACTH fragment and is examined largely for neurotrophic and neuromodulatory signalling, with frequent reference to BDNF-related pathways in the literature. Selank originates from tuftsin and is examined largely for GABAergic and neuroimmune signalling. These are different starting points and different research questions, even though both compounds fall within the same broad neuropeptide class.
Because the mechanisms studied are distinct rather than overlapping, direct head-to-head comparison of 'potency' or 'effect' is not meaningful in the research framing. The compounds are not interchangeable, and the literature does not treat one as a stronger version of the other. Any comparison is best understood as a contrast of mechanistic hypotheses under investigation, not a ranking.
Why they are grouped as 'Russian nootropic peptides'
The 'Russian nootropic peptides' label is a discussion convention rather than a scientific classification. It reflects that both compounds emerged from Russian research programmes, that both are short peptides administered in research settings, and that both are studied for central-nervous-system signalling. This shared context makes them convenient to describe together, particularly in comparative reviews and supplier catalogues.
The grouping can be misleading if it implies mechanistic equivalence. A more accurate framing is that Semax and Selank are two separate research neuropeptides that happen to share an origin story and a structural class. Recognising the different parent molecules, ACTH fragment versus tuftsin, is the key to reading the literature on each without conflating their studied properties.
Molecular identity and how each is supplied
Both Semax and Selank are classed among short synthetic neuropeptides and are typically supplied as lyophilised (freeze-dried) powders for laboratory research. Each has a defined amino-acid sequence and molecular formula corresponding to its analogue design, and each is identified in research contexts by that sequence rather than by any brand name. Purity and identity are the properties most relevant to a research buyer, since they determine whether experimental results can be attributed to the intended compound.
For this reason, analytical documentation matters more than marketing description. Independent testing methods such as high-performance liquid chromatography (HPLC) for purity and mass spectrometry for identity are commonly referenced on Certificates of Analysis. Sova Peptides supplies both Semax and Selank for research use, each with a batch-linked Certificate of Analysis, so that the specific material in hand can be traced to its own test data rather than to a generic specification.
Research-use disclaimer
The information in this article is provided for educational and research reference only. It describes mechanisms and findings reported in the scientific literature and does not constitute medical, therapeutic, or dosing advice. Semax and Selank are research compounds and are not medicines; nothing here should be interpreted as a claim of benefit, safety, or suitability for use in humans or animals.
Any handling of these compounds is intended strictly for qualified researchers operating in appropriate laboratory settings and in accordance with applicable laws and institutional guidelines. Readers should consult primary literature and relevant regulations before undertaking any research work.
Frequently asked
Are Semax and Selank the same type of peptide?
They belong to the same broad class of short synthetic neuropeptides and are both studied for central-nervous-system signalling, but they are not the same compound. They derive from different parent molecules and are examined along different mechanistic pathways.
What is the parent molecule of Semax?
Semax is derived from a fragment of adrenocorticotropic hormone (ACTH), specifically an analogue related to the ACTH(4-10) sequence, modified for greater stability than the native fragment.
What is the parent molecule of Selank?
Selank is a synthetic analogue of tuftsin, a naturally occurring peptide fragment associated with immunomodulatory activity, again modified structurally relative to the native sequence.
How do the studied mechanisms differ?
In the literature, Semax is most often examined in relation to neurotrophic and neuromodulatory signalling, including BDNF-related pathways, while Selank is studied more in relation to GABAergic and neuroimmune signalling. These are distinct research questions rather than overlapping ones.
Why are they called 'Russian nootropic peptides'?
The label reflects their shared origin in Russian research programmes and their common study as short peptides acting on the central nervous system. It is a discussion convention and does not imply that the two compounds work by the same mechanism.
Is one of them stronger or better than the other?
No superiority comparison is meaningful in the research framing. Because they descend from different parent molecules and are studied for different pathways, they are not interchangeable and neither is treated as a stronger version of the other.
How are Semax and Selank typically supplied for research?
Both are usually supplied as lyophilised powders for laboratory research, each identified by its defined amino-acid sequence and molecular formula, and each ideally accompanied by analytical documentation confirming purity and identity.
Why does a Certificate of Analysis matter for these peptides?
A batch-linked Certificate of Analysis lets a researcher trace the specific material to its own test data, typically HPLC for purity and mass spectrometry for identity, so that experimental observations can be attributed to the intended compound. Sova Peptides supplies both Semax and Selank for research with such documentation.